Cost Effectiveness Plays Key Role In Evidence Assessments
This article was originally published in The Gray Sheet
Executive Summary
Executives from the medical device and payer communities weigh in on the importance of cost-effectiveness as well as clinical-effectiveness research.
You may also be interested in...
The Path To Cost Comparisons Can Go Through PCORI, Experts Say
While some seek creative means to leverage the recently created Patient Centered Outcomes Research Institute to encourage cost comparisons of technology and services, others say there are no real barriers to doing so.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.